Vericel

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Earnings data Q1 2023

Earnings data Q2 2023

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 12:30 p.m. ET (9:30 a.m. PT) on Tuesday, March 7, 2023.

Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023

Vericel Corporation (NASDAQ:VCEL ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Eric Burns – Head-Financial Planning and Analysis and Investor Relations. Nick Colangelo – President and Chief Executive Officer Joe Mara – Chief Financial Officer Conference Call Participants Ryan Zimmerman – BTIG Sam Brodovsky – Truist Securities Jeffrey Cohen – Ladenburg Sean Lee – HC Wainwright Operator Ladies and gentlemen, thank you for standing by.

Vericel Corporation (VCEL) Q4 2022 Earnings Call Transcript

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 500% and 0.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Q4 Earnings Surpass Estimates

Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth

Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter 2022 financial results on Thursday, February 23, 2023. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results and certain business highlights.

Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023

Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?

Full-Year Total Revenue Expected to be Approximately $164 to $165 Million

Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Kytopen, an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to Chair the Kytopen Board of Directors. Following the appointment of Dr. Wotton, the Board will comprise of five directors including Ann DeWitt, Adam Wieschhaus, Cullen Buie, and Paulo Garcia.

Kytopen Appoints Paul K. Wotton, Ph.D.

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 41st Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to begin at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 11, 2023.

Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023

Various ongoing fundamental improvements signal significant upsides. The recent NexoBrid approval foretells leaping sales growth in the coming quarters.

Vericel: Aggressive Growth In 2023

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns

Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference.

Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference

Vericel Corporation (NASDAQ:VCEL ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investor Relations Nick Colangelo - President & Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Sam Brodovsky - Truist Securities Jeffrey Cohen - Ladenburg Thalmann George Sellers - Stephens Operator Ladies and gentlemen, thank you for standing by. Welcome to the Vericel's Third Quarter 2022 Conference Call.

Vericel Corporation (VCEL) Q3 2022 Earnings Call Transcript

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -16.67% and 3.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Reports Q3 Loss, Lags Revenue Estimates

Total Net Product Revenue of $38.6 Million

Vericel Reports Third Quarter 2022 Financial Results

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2022 financial results on Wednesday, November 9, 2022. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results and certain business highlights.

Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief Financial Officer Joe Mara will present at the upcoming Ladenburg Thalmann Healthcare Conference. The presentation is scheduled to begin at 2:30 p.m. ET on Thursday, September 29, 2022.

Vericel to Present at the Ladenburg Thalmann Healthcare Conference

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Morgan Stanley and H.C. Wainwright investor conferences.

Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences

The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Vericel Corporation (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Vericel Corporation (VCEL)? Wall Street Analysts Think 53%

Vericel Corporation (NASDAQ:VCEL ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investor Relations Nick Colangelo - President & Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Sam Bedovsky - Truist Jeffrey Cohen - Ladenburg Thalmann Arthur He - HCW Operator Ladies and gentlemen, thank you for standing by. Welcome to the Vericel's Second Quarter 2022 Conference Call.

Vericel Corporation (VCEL) CEO Nick Colangelo on Q2 2022 Results - Earnings Call Transcript

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -46.15% and 3.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates

Second Quarter Total Net Revenue of $37.0 Million

Vericel Reports Second Quarter 2022 Financial Results

CAMBRIDGE, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the publication of results from a retrospective study conducted by the Burn and Reconstructive Centers of America (BRCA) of 40 patients with large posterior trunk burns treated with Epicel® (cultured epidermal autografts) in the Journal of Burn Care & Research . Severe burns on posterior trunk surfaces present special consideration since the posterior surfaces bear the major portion of the body weight. The study evaluated the success of engraftment in patients receiving Epicel for posterior trunk burns with total burn surface area (TBSA) ≥30% treated at three high-volume burn centers within the BRCA between March 2016 and December 2019.

Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel

CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2022 financial results on Wednesday, August 3, 2022. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results and business highlights.

Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022

Vericel Corp (NASDAQ:VCEL ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Eric Burns - Executive Director, Financial Planning and Analysis & IR Dominick Colangelo - CEO, President & Director Joseph Mara - CFO & Treasurer Conference Call Participants Ryan Zimmerman - BTIG Christopher Cooley - Stephens Inc. Jeffrey Cohen - Ladenburg Thalmann & Co. Danielle Antalffy - SVB Leerink Samuel Brodovsky - Truist Securities Arthur He - H.C. Wainwright & Co. Operator Ladies and gentlemen, thank you for standing by.

News for Vericel Stock (VCEL)